Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
- PMID: 24201163
- DOI: 10.1016/j.clbc.2013.09.010
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
Keywords: HER2; Inflammatory breast cancer; Lapatinib; Next-generation sequencing; Trastuzumab.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
